Filing Details

Accession Number:
0001127602-18-015376
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-04-27 07:48:58
Reporting Period:
2018-04-25
Accepted Time:
2018-04-27 07:48:58
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875045 Biogen Inc. BIIB Biological Products, (No Disgnostic Substances) (2836) 330112644
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1361754 J Alexander Denner C/O Sarissa Capital Management Lp
660 Steamboat Road
Greenwich CT 06830
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-04-25 48,000 $269.91 461,858 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnotes
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 10,029 Direct
Footnotes
  1. On April 25, 2018, funds managed by Sarissa Capital Management LP (such funds, the "Sarissa Funds") purchased an aggregate of 48,000 shares of common stock of Biogen Inc. All of the shares reported herein as being indirectly beneficially owned by Dr. Denner are directly beneficially owned by the Sarissa Funds.
  2. Dr. Denner is the Chief Investment Officer of Sarissa Capital Management LP and the managing member of the general partner of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 of the Securities Exchange Act of 1934, as amended) the shares that the Sarissa Funds directly beneficially own. Dr. Denner disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.